Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions. TEVA ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Prior to market opening, Teva (NYSE:TEVA) announced a 3.8-percent increase in revenues to $16.5 billion from the $15.9 ...

In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands among Wednesday’s worst-performing stocks. The stock market declined on Wednesday ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...

北京时间2025年01月31日02时31分，梯瓦制药（TEVA.us）股票出现异动，股价大幅下挫5.04%。截至发稿，该股报17.61美元/股，成交量2073.05万股， 换手率 1.83%，振幅5.23%。

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...

SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a leading innovator in transportation safety technology, today announced the award of a new contract with Teva Pharmaceutical Industries Ltd. (Teva), to ...

Israeli generics giant Teva Pharmaceutical Industries today reported results for the year and the quarter ended December 31, ...